Furosemide Use in Acute Kidney Injury

Indications and Contraindications

• The KDIGO 2014 guideline recommends that loop diuretics not be used to prevent or treat AKI, except when they are needed to manage clinically evident volume overload such as pulmonary crackles, elevated jugular venous pressure, peripheral edema, or a positive fluid balance 1.
• In patients with AKI without volume overload, furosemide is contraindicated because it does not improve renal recovery or reduce mortality 1.
• Predictors of poor diuretic response (and thus relative contraindications) include:
  
  • Systolic blood pressure < 90 mm Hg 2
  • Severe hyponatraemia (serum Na < 130–135 mmol/L) 2
  • Metabolic acidosis 2
  • Dialysis‑dependent AKI or serum creatinine > 3 mg/dL with oliguria 3

Dosing and Administration

• Initial bolus for diuretic‑naïve patients: 20–40 mg IV 2.
• For patients already on chronic oral loop diuretics, give at least twice the total daily oral dose intravenously (e.g., 40 mg PO → ≥ 80 mg IV) 2.
• Dose escalation: double the IV dose every 2–3 days until urine output reaches ≥ 0.5 mL/kg/h 2.

Maximum Daily Limits (derived from European Heart Failure data)

These limits are supported by the European Journal of Heart Failure 2.

• Continuous infusion alternative: loading dose 40 mg IV, then 5–20 mg/h (maximum 40 mg/h) 3. Continuous infusion is at least as effective as intermittent bolus and may be superior in severe cases 3.

Monitoring

• Every 1–4 h: urine output (hourly, preferably via catheter), blood pressure, and bedside assessment of congestion (lung crackles, JVP, edema) 2.
• Daily: body weight (same time each day), serum electrolytes (K⁺, Na⁺, Mg²⁺), and renal function (creatinine, BUN) 2.
• Interpretation of creatinine trends: a rise < 30 % from baseline during effective decongestion is expected and does not mandate stopping furosemide 3; a rise > 30 % with persistent congestion indicates worsening heart failure and warrants intensifying therapy 3.

Management of Diuretic Resistance (Sequential Nephron Blockade)

• Add a thiazide‑type diuretic when loop diuretic alone is insufficient:
  
  • Metolazone 2.5–5 mg PO once or twice daily 2
  • OR chlorothiazide 500–1,000 mg IV once or twice daily 2
  • OR hydrochlorothiazide 25 mg PO 2
• Add an aldosterone antagonist (spironolactone or eplerenone) 25–50 mg PO daily to enhance natriuresis and mitigate hypokalaemia 2.
• Low‑dose combination therapy (loop + thiazide ± aldosterone antagonist) is more effective and produces fewer adverse effects than high‑dose loop monotherapy 2.

Safety and Adverse Effects

• Electrolyte disturbances:
  
  • Hypokalaemia is the most common adverse effect; aggressive replacement is required 2.
  • Hypomagnesaemia frequently accompanies hypokalaemia and should be corrected 3.
  • High‑dose furosemide may worsen hyponatraemia 2.
• Ototoxicity prevention: do not exceed 6 mg/kg/day for more than 1 week, and administer the dose over 5–30 minutes to reduce hearing loss risk 3.
• Drug interactions: NSAIDs blunt diuretic response and worsen renal function; they must be avoided 4. ACE inhibitors or ARBs may be continued unless the patient develops hemodynamic instability 4.

Outcomes and Therapeutic Goals

• Randomized trials show that furosemide does not prevent AKI and may increase mortality when used prophylactically 1.
• In AKI patients with acute lung injury, using furosemide together with a conservative fluid strategy is associated with lower mortality 1.
• The primary therapeutic goal is to achieve clinical euvolemia (normal JVP, resolution of peripheral edema, no pulmonary crackles) before discharge 3.
• Maintaining stable electrolytes and renal function according to the monitoring schedule helps reduce rehospitalisation and mortality risk 3.
• Furosemide does not improve renal recovery; its role is limited to symptomatic management of volume overload 1.

Use of Furosemide in HFpEF Patients with Acute Kidney Injury

Predictors of Poor Diuretic Response

• Systolic blood pressure < 90 mm Hg predicts a reduced response to loop diuretics and warrants extreme caution when using furosemide in HFpEF with AKI. 5
• Severe hyponatremia (serum sodium < 130–135 mmol/L) is associated with poor diuretic efficacy and increased risk of renal deterioration. 6
• Metabolic acidosis is another independent predictor of inadequate diuretic response in this population. 5

Initial Dosing and Early Dose Limits

• Diuretic‑naïve patients: start with a 20–40 mg intravenous bolus of furosemide administered over 1–2 minutes. 6
• Patients already on oral loop diuretics: give an intravenous dose that is at least twice the total daily oral dose (e.g., 40 mg PO → ≥ 80 mg IV). 5
• Early cumulative dose limits to reduce toxicity:
  
  • First 6 hours → ≤ 100 mg total IV dose. 6
  • First 24 hours → ≤ 240 mg total IV dose. 5

Monitoring Protocol (Intensive Surveillance)

• Every 1–4 hours: record urine output (catheter recommended), blood pressure, and perform a bedside assessment for congestion (lung crackles, jugular venous pressure, peripheral edema). 5
• Daily: obtain body weight (same time each day), serum electrolytes (potassium, sodium, magnesium), renal function tests (creatinine, BUN), and a strict intake‑output chart. 6

Management of Diuretic Resistance (Sequential Nephron Blockade)

• Step 1 – Loop escalation: double the IV furosemide dose every 2–3 days until urine output reaches ≥ 0.5 mL/kg/h. 5
• Step 2 – Add a thiazide‑type diuretic:
  
  • Metolazone 2.5–5 mg orally once or twice daily, or
  • Chlorothiazide 500–1,000 mg intravenously once or twice daily, or
  • Hydrochlorothiazide 25 mg orally. 6
• Step 3 – Add an aldosterone antagonist: spironolactone or eplerenone 25–50 mg orally daily to enhance natriuresis and mitigate hypokalemia. 5
• Low‑dose combination therapy (loop + thiazide ± aldosterone antagonist) is more effective and produces fewer adverse effects than high‑dose loop monotherapy. 6

Electrolyte Management and Drug Interactions

• Hypokalemia is the most frequent adverse effect of high‑dose furosemide; aggressive potassium replacement is required. 5
• Hyponatremia may worsen with intensive diuretic regimens; monitor serum sodium closely. 5
• NSAIDs should be avoided because they blunt diuretic response and exacerbate renal dysfunction. 5
• ACE inhibitors, ARBs, and β‑blockers can be continued unless the patient develops hemodynamic instability. 5

Guideline Evidence Summary (HFpEF)

• A 2024 systematic review of HFpEF guidelines concluded that diuretics provide symptomatic relief but have no proven prognostic benefit and may trigger neuro‑hormonal activation, underscoring a delicate risk‑benefit balance in AKI. Evidence level: systematic review (moderate). 7
• The same 2024 guideline review highlighted ongoing disagreement among societies regarding the chronic use of aldosterone antagonists in HFpEF, indicating that their role remains uncertain. Evidence level: guideline consensus (low‑moderate). 7